BioStock: BioInvent’s CMO on the positive FDA decision

BioInvent has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the anti-FcyRllB antibody BI-1206 in the treatment of the most common form of slow-growing non-Hodgkin’s lymphoma, follicular lymphoma. BioStock reached out to BioInvent’s Chief Medical Officer Andres McAllister, who talks about the importance of the FDA decision.

Read the full interview with Andres McAllister at biostock.se:

https://www.biostock.se/en/2022/01/bioinvents-cmo-on-the-positive-fda-decision/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/